002773 康弘药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入3,623,8666.23%4,452,6583,957,4603,389,0283,605,347
减:营业总成本2,438,5445.48%3,160,1302,807,0682,475,9023,165,611
    其中:营业成本350,4781.50%466,463438,409388,035354,606
               财务费用(41,527)-10.46%(62,341)(52,353)(44,944)(34,328)
               资产减值损失(1,218)63.20%(2,778)(231)(4,127)(216,033)
公允价值变动收益(720)-48.08%(1,056)(833)----
投资收益11,064-45.54%47,27845,03238,06426,426
    其中:对联营企业和合营企业的投资收益(469)134.29%(336)(207)(748)(620)
营业利润1,228,0946.91%1,381,3301,261,0681,015,368355,177
利润总额1,208,4516.17%1,352,5371,233,9171,030,296393,420
减:所得税费用187,3268.11%175,529202,793164,485(27,660)
净利润1,021,1245.83%1,177,0081,031,124865,811421,081
减:非控股权益(11,782)33.56%(14,223)(13,642)(30,859)(4)
股东净利润1,032,9076.08%1,191,2311,044,766896,670421,084

市场价值指针
每股收益 (元) *1.1205.66%1.3001.1400.9800.460
每股派息 (元) *----0.6000.3800.1500.100
每股净资产 (元) *9.9498.48%9.4088.4887.5066.623
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容